Iovance Biotherapeutics announced that the FDA has granted fast track designation for LN-145 for the treatment of patients with recurrent, metastatic or persistent cervical cancer who have progressed while on or after chemotherapy. LN-145 is the company’s adoptive cell therapy produced using its proprietary TIL manufacturing technology.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.